<産業資料/調査レポートの題名> 2022年7月19日

生物学的治療薬の世界市場2018-2022


◆英文タイトル:Global Biologic Therapeutics Market 2018-2022

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 05: PIPELINE ANALYSIS
PART 06: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 08: MARKET SEGMENTATION BY TYPE OF THERAPEUTIC AGENT
• Segmentation by therapeutic agent
• Comparison by therapeutic agent
• Monoclonal antibodies – Market size and forecast 2017-2022
• Others – Market size and forecast 2017-2022
• Vaccines – Market size and forecast 2017-2022
• Cell and tissue-based therapy – Market size and forecast 2017-2022
• Gene therapy – Market size and forecast 2017-2022
• Market opportunity by therapeutic agent
PART 09: MARKET SEGMENTATION BY APPLICATION
• Oncology
• Autoimmune and inflammatory diseases
• Hematology
• Others
PART 10: CUSTOMER LANDSCAPE
PART 11: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Americas – Market size and forecast 2017-2022
• EMEA – Market size and forecast 2017-2022
• APAC – Market size and forecast 2017-2022
• Market opportunity
PART 12: DECISION FRAMEWORK
PART 13: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 14: MARKET TRENDS
PART 15: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 16: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• AbbVie
• Johnson & Johnson
• Merck
• Pfizer
PART 17: APPENDIX
• List of abbreviations
Exhibit 01: Parent market
Exhibit 02: Global biologic therapeutics market: Segmentation
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Biologics in pipeline 2017-2018
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2017
Exhibit 08: Validation techniques employed for market sizing 2017
Exhibit 09: Global – Market size and forecast 2017-2022 ($ bn)
Exhibit 10: Global – Year-over-year growth 2018-2022 (%)
Exhibit 11: Five forces analysis 2017
Exhibit 12: Five forces analysis 2022
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition – Five forces 2017
Exhibit 19: Global biologic therapeutics market – Market share by therapeutic agent 2017-2022 (%)
Exhibit 20: Comparison by therapeutic agent
Exhibit 21: Monoclonal antibodies – Market size and forecast 2017-2022 ($ bn)
Exhibit 22: Sales of major monoclonal antibodies 2015-2017
Exhibit 23: Monoclonal antibodies – Year-over-year growth 2018-2022 (%)
Exhibit 24: Others – Market size and forecast 2017-2022 ($ bn)
Exhibit 25: Others – Year-over-year growth 2018-2022 (%)
Exhibit 26: Vaccines – Market size and forecast 2017-2022 ($ bn)
Exhibit 27: Vaccines – Year-over-year growth 2018-2022 (%)
Exhibit 28: Cell and tissue-based therapy – Market size and forecast 2017-2022 ($ bn)
Exhibit 29: Cell and tissue-based therapy – Year-over-year growth 2018-2022 (%)
Exhibit 30: Gene therapy– Market size and forecast 2017-2022 ($ bn)
Exhibit 31: Gene therapy– Year-over-year growth 2018-2022 (%)
Exhibit 32: Market opportunity by type of therapeutic agent
Exhibit 33: Sales of biologics used in oncology 2015-2017 ($ millions)
Exhibit 34: Customer landscape
Exhibit 35: Global biologic therapeutics market – Market share by geography 2017-2022 (%)
Exhibit 36: Regional comparison
Exhibit 37: Americas – Market size and forecast 2017-2022 ($ bn)
Exhibit 38: Americas – Year-over-year growth 2018-2022 (%)
Exhibit 39: Top three countries in Americas
Exhibit 40: EMEA – Market size and forecast 2017-2022 ($ bn)
Exhibit 41: EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 42: Top three countries in EMEA
Exhibit 43: APAC – Market size and forecast 2017-2022 ($ bn)
Exhibit 44: APAC – Year-over-year growth 2018-2022 (%)
Exhibit 45: Top three countries in APAC
Exhibit 46: Market opportunity
Exhibit 47: Treatment costs of some recently approved biologics in US
Exhibit 48: Patent expiration dates of some biologics
Exhibit 49: Vendor landscape
Exhibit 50: Landscape disruption
Exhibit 51: Vendor classification
Exhibit 52: Market positioning of vendors
Exhibit 53: AbbVie overview
Exhibit 54: AbbVie – Business segments
Exhibit 55: AbbVie – Organizational developments
Exhibit 56: AbbVie – Geographic focus
Exhibit 57: AbbVie – Key offerings
Exhibit 58: Johnson & Johnson overview
Exhibit 59: Johnson & Johnson – Business segments
Exhibit 60: Johnson & Johnson – Organizational developments
Exhibit 61: Johnson & Johnson Geographic focus
Exhibit 62: Johnson & Johnson – Segment focus
Exhibit 63: Johnson & Johnson – Key offerings
Exhibit 64: Merck overview
Exhibit 65: Merck – Business segments
Exhibit 66: Merck – Organizational developments
Exhibit 67: Merck – Geographic focus
Exhibit 68: Merck – Segment focus
Exhibit 69: Merck – Key offerings
Exhibit 70: Pfizer overview
Exhibit 71: Pfizer – Business segments
Exhibit 72: Pfizer – Organizational developments
Exhibit 73: Pfizer – Geographic focus
Exhibit 74: Pfizer – Segment focus
Exhibit 75: Pfizer – Key offerings



LINEで送る
Share on LinkedIn
このエントリーをはてなブックマークに追加
Bookmark this on BuzzURL
Bookmark this on Yahoo Bookmark